Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
AMP-005 is a Phase 1b/2 clinical trial designed to evaluate whether the new drug, imexon, can
be administered in combination with the approved drug, dacarbazine (DTIC), for the treatment
of patients with stage III or IV inoperable melanoma. The Phase 1b part of the study is
designed to determine whether the two drugs can be safely combined together, and the Phase 2
part of the study is designed to provide additional safety data and to gain an understanding
of whether adding imexon to DTIC can improve the outcome for melanoma patients versus the
findings from prior clinical studies of DTIC alone.